Tag: cdx

GATK Mutect2 mouse dbSNP vcf files recommendations for mouse whole exome data

GATK Mutect2 mouse dbSNP vcf files recommendations for mouse whole exome data 0 Dear all, Is there any best practice for the mouse snp indel vcf files using GATK Mutect2 for mouse whole exome data? For mm10, it seems have several available, for mm39, it seems the newest is from…

Continue Reading GATK Mutect2 mouse dbSNP vcf files recommendations for mouse whole exome data

Rhumbline Advisers Sells 980 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Rhumbline Advisers decreased its stake in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 0.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 267,994 shares of the company’s stock after selling 980 shares during…

Continue Reading Rhumbline Advisers Sells 980 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

DESEQ2 design in DESeqDataSetFromMatrix: cell and treatment

DESEQ2 design in DESeqDataSetFromMatrix: cell and treatment 0 Hello, I have RNAseq coming from CDX models that were treated with DMSO and another compound (condition). I have 12 CDX models in total, 6 were implanted with cell1 (4 DMSO, 2 treated) and 6 with cell2 (3DMSO, 3 treated). I would…

Continue Reading DESEQ2 design in DESeqDataSetFromMatrix: cell and treatment

Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial

Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017;49:1476–86. Article  CAS  PubMed  PubMed Central  Google Scholar  Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, et…

Continue Reading Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial

Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting

NATICK, Mass., Nov. 8, 2023 /PRNewswire/ — Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City,…

Continue Reading Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting

The best medtech innovations of 2023

2023’s best medtech innovations Category: Best Medical TechnologyWinner: Guardant360 CDx Guardant Health’s Guardant360 CDx [Photo courtesy of Guardant Health] Guardant Health’s Guardant360 CDx beat out 27 other nominees in the best medical technology category, which included products from Boston Scientific, Edwards Lifesciences and Olympus (more on those in a bit)….

Continue Reading The best medtech innovations of 2023

Myriad Genetics (NASDAQ:MYGN) Sets New 1-Year Low at $13.82

Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) shares reached a new 52-week low during trading on Friday . The stock traded as low as $13.82 and last traded at $13.96, with a volume of 12469 shares traded. The stock had previously closed at $14.21. Wall Street Analyst Weigh In…

Continue Reading Myriad Genetics (NASDAQ:MYGN) Sets New 1-Year Low at $13.82

allow-no-covars not recognized when using plink2 glm without covariates

Hi! I would like to run association tests without covariates, to show the effect of population stratification correction. When I first tried doing this,  I was instructed to use the ‘allow-no-covars’ modifier. However, when I run my command including this modifier, I get the error Error: Unrecognized flag (‘–allow-no-covars’). The…

Continue Reading allow-no-covars not recognized when using plink2 glm without covariates

Boehringer Ingelheim, Thermo Fisher to collaborate on CDx development for NSCLC

Boehringer Ingelheim and Thermo Fisher have formed a partnership to develop companion diagnostic (CDx) tests for identifying patients with non-small cell lung cancer (NSCLC) with specific genomic mutations who may benefit from targeted therapies as they become available. Under the agreement, the two companies will develop multiple CDx tests based…

Continue Reading Boehringer Ingelheim, Thermo Fisher to collaborate on CDx development for NSCLC

Predicine announces six studies showcasing MRD and liquid

HAYWARD, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) — Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain. The company will present six compelling poster studies, unveiling the future of liquid biopsy solutions. These poster presentations will…

Continue Reading Predicine announces six studies showcasing MRD and liquid

ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease

A 2020 Nature Cancer study found that patients with advanced non-small cell lung cancer (NSCLC) who had undetectable circulating tumor (ct)DNA after chemoradiotherapy “had excellent outcomes whether or not they received consolidation immune checkpoint inhibition (CICI) … the ctDNA response pattern early during CICI identified patients responding to consolidation therapy.”…

Continue Reading ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease

Ronald Blue Trust Inc. Significantly Reduces Stake in Myriad Genetics, Inc.: A Glimpse into Investment Strategy and Market Dynamics

October 2, 2023 Myriad Genetics, Inc. Experiences a Significant Reduction in Stake by Ronald Blue Trust Inc. On October 2, 2023, it was reported that financial services firm Ronald Blue Trust Inc. has significantly lessened its stake in Myriad Genetics, Inc. (NASDAQ: MYGN). According to the company’s most recent 13F…

Continue Reading Ronald Blue Trust Inc. Significantly Reduces Stake in Myriad Genetics, Inc.: A Glimpse into Investment Strategy and Market Dynamics

Q1 2024 EPS Estimates for Myriad Genetics, Inc. Reduced by Leerink Partnrs (NASDAQ:MYGN)

Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) – Stock analysts at Leerink Partnrs lowered their Q1 2024 earnings per share estimates for shares of Myriad Genetics in a report released on Wednesday, September 20th. Leerink Partnrs analyst P. Souda now anticipates that the company will earn ($0.15) per share for…

Continue Reading Q1 2024 EPS Estimates for Myriad Genetics, Inc. Reduced by Leerink Partnrs (NASDAQ:MYGN)

Duality Advisers LP Reduces Holdings in Myriad Genetics, Inc.

September 19, 2023 – Duality Advisers LP, a prominent financial advisory firm, has recently announced a significant reduction in its holdings of Myriad Genetics, Inc. (NASDAQ:MYGN). According to the company’s Form 13F filing with the Securities & Exchange Commission, Duality Advisers LP sold off 33,315 shares during the first quarter…

Continue Reading Duality Advisers LP Reduces Holdings in Myriad Genetics, Inc.

Myriad Genetics (NASDAQ:MYGN) Shares Down 3.2%

Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report)’s stock price traded down 3.2% during mid-day trading on Friday . The stock traded as low as $15.95 and last traded at $15.95. 10,102 shares traded hands during trading, a decline of 98% from the average session volume of 550,781 shares. The…

Continue Reading Myriad Genetics (NASDAQ:MYGN) Shares Down 3.2%

Acutis Biosciences’ CSO Dr. Abdel Halim Co-Authors a Precision Medicine Study in NEJM

Highlights the value of companion diagnostics in the drug industry and the effectiveness of ctDNA testing in blood samples instead of invasive tumor biopsies for patient screening in clinical trials, The assay demonstrated ctDNA liquid biopsy can be an alternative or complement to tissue samples and decrease sample failure rate, Laboratory…

Continue Reading Acutis Biosciences’ CSO Dr. Abdel Halim Co-Authors a Precision Medicine Study in NEJM

Increased Stake in Myriad Genetics: A Promising Investment for HRT Financial LP

On September 7, 2023, it was reported that HRT Financial LP had increased its stake in Myriad Genetics, Inc. by a staggering 176.3% during the first quarter of the year. This information was disclosed in the company’s most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional…

Continue Reading Increased Stake in Myriad Genetics: A Promising Investment for HRT Financial LP

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC

3D illustration of lung tumor © SciePro – stock.adobe.com Progression-free survival (PFS) results with brigatinib (Alunbrig) were not superior to that observed with alectinib (Alecensa) in crizotinib (Xalkori)-pretreated patients with ALK-positive non–small cell lung cancer (NSCLC), according to findings from the phase 3 ALTA-3 study (NCT03596866).1 Though brigatinib was not…

Continue Reading Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC

Myriad Genetics Receives Mixed Ratings from Analysts; Reports Quarterly Financial Results

Myriad Genetics, Inc. (NASDAQ:MYGN) has recently received an average rating of “Hold” from a group of five ratings firms covering the company, as reported by Bloomberg Ratings on September 1, 2023. Out of the five research analysts, one has rated the stock as a sell, two have given it a…

Continue Reading Myriad Genetics Receives Mixed Ratings from Analysts; Reports Quarterly Financial Results

Credit Suisse AG Reduces Holdings in Myriad Genetics, Inc.: An Investment Strategy Shift

Credit Suisse AG, a global financial services company, recently disclosed a reduction in its holdings of Myriad Genetics, Inc. According to its 13F filing with the Securities and Exchange Commission (SEC), the firm decreased its ownership by 17.7% during the first quarter of this year. As a result, Credit Suisse…

Continue Reading Credit Suisse AG Reduces Holdings in Myriad Genetics, Inc.: An Investment Strategy Shift

California State Teachers Retirement System Sells 1,080 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

California State Teachers Retirement System decreased its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 1.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 100,776 shares of the company’s stock after selling 1,080 shares…

Continue Reading California State Teachers Retirement System Sells 1,080 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Screening Market Poised for Remarkable 12.4% CAGR Surge, Projected to Reach US$ 4.32 Billion by 2033 | FMI

  The global Carrier Screening Market is expected to record a CAGR of 12.4% between 2023 and 2033, with a size estimated in 2023 at US$ 1,343.40 million. The market’s value is expected to rise to US$ 4,323.84 million by 2033. As a result of increased funding from the public and…

Continue Reading Screening Market Poised for Remarkable 12.4% CAGR Surge, Projected to Reach US$ 4.32 Billion by 2033 | FMI

SG Americas Securities LLC Reduces Stake in Myriad Genetics, Inc.: Sparking Speculation and Curiosity Among Investors and Analysts

In a surprising turn of events, &SG Americas Securities LLC has decided to reduce its stake in Myriad Genetics, Inc. by a significant 33.5% during the first quarter of this fiscal year. This move has caught the attention of investors and industry analysts alike, sparking speculation about the motives behind…

Continue Reading SG Americas Securities LLC Reduces Stake in Myriad Genetics, Inc.: Sparking Speculation and Curiosity Among Investors and Analysts

2023-08-03 | NDAQ:MYGN | Press Release

Highlights: Second quarter testing volume grew 17% year-over-year, excluding contributions from the SneakPeek® Early Gender DNA Test. In the second quarter: Hereditary cancer test volumes grew 20% year-over-year, the third consecutive quarter of double-digit growth year-over-year. GeneSight® pharmacogenomics test volumes grew 23% year-over-year. Prenatal test volumes grew 12% year-over-year, excluding…

Continue Reading 2023-08-03 | NDAQ:MYGN | Press Release

2023-08-02 | NDAQ:KPTI | Press Release

– Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – – Maintains Full Year 2023 Total Revenue Guidance of $145 Million to $160 Million, Including U.S. XPOVIO Net Product Revenue Guidance of $110 Million to $125 Million – –…

Continue Reading 2023-08-02 | NDAQ:KPTI | Press Release

Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research – Guardant Health (NASDAQ:GH), Illumina (NASDAQ:ILMN)

Guardant Health, Inc. GH, a leading precision oncology company, today announced an agreement with Illumina Inc. ILMN, a global leader in DNA sequencing and array-based technologies, that resolves their pending litigation and promotes a shared resolution to advance the companies’ long-term, commercial partnership. The three-year agreement includes a joint request…

Continue Reading Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research – Guardant Health (NASDAQ:GH), Illumina (NASDAQ:ILMN)

Arizona State Retirement System Acquires 726 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Arizona State Retirement System raised its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 3.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,479 shares of the company’s stock after acquiring an…

Continue Reading Arizona State Retirement System Acquires 726 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options

SAN DIEGO, July 25, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of Decision Medicine™, today announced a strategic partnership to make Pillar’s suite of oncology assays commercially available globally as part of the Illumina portfolio…

Continue Reading Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options

Circulating Cell-Free Tumor DNA Analysis Market to Reach $25.88 Billion by 2030, Says Coherent Market Insights (CMI)

Circulating Cell-Free Tumor DNA Analysis Market to Reach $25.88 Billion by 2030, Says Coherent Market Insights (CMI) Burlingame, July 25, 2023 (GLOBE NEWSWIRE) — Coherent Market Insights published a report, titled, “Circulating Cell-Free Tumor DNA Market, by Tumor Type (Malignant Tumors, Precancerous Tumors), by Cancer Type (Lung Cancer, Colorectal Cancer, Breast…

Continue Reading Circulating Cell-Free Tumor DNA Analysis Market to Reach $25.88 Billion by 2030, Says Coherent Market Insights (CMI)

Myriad Genetics: Rising Price Objective and Promising Growth in the Precision Medicine Industry

In a recent report released on July 23, 2023, financial analysts at The Goldman Sachs Group have increased their price objective for Myriad Genetics (NASDAQ:MYGN) from $25.00 to $28.00. This comes as exciting news for investors, as it suggests a potential upside of 26.24% from the current price of the…

Continue Reading Myriad Genetics: Rising Price Objective and Promising Growth in the Precision Medicine Industry

Navigating the Future of Genetic Testing and Precision Medicine: A Closer Look at Myriad Genetics, Inc.’s Performance and Offerings

Myriad Genetics, Inc. (NASDAQ:MYGN) continues to navigate the ever-evolving landscape of genetic testing and precision medicine with its innovative approach and commitment to advancing healthcare. The recent reduction in stake by Strs Ohio, as disclosed in its most recent filing with the Securities and Exchange Commission (SEC), indicates a shift…

Continue Reading Navigating the Future of Genetic Testing and Precision Medicine: A Closer Look at Myriad Genetics, Inc.’s Performance and Offerings

Genetic Testing Market Surges with Promising Prospects

PRESS RELEASE Published July 22, 2023 The global Genetic Testing Market size is predicted to reach USD 29.44 billion by 2030 with a CAGR of 11.1% from 2020-2030. The report offers valuable business perspectives on various macroeconomic factors impacting the industry and provides an overview of world economies. It delves…

Continue Reading Genetic Testing Market Surges with Promising Prospects

Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA USA – English India – English

SAN DIEGO, July 21, 2023 /PRNewswire/ — Invivoscribe is excited to announce that the LeukoStrat® CDx FLT3 Mutation Assay has been approved by the U.S. Food and Drug Administration (FDA) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be eligible to…

Continue Reading Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA USA – English India – English

KIT Mutations and Treatment Outcomes in Advanced Gastrointestinal Stromal Tumor

The following is a summary of “Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib,” published in the July 2023 issue of the Oncology by Serrano et al. The current treatment paradigm…

Continue Reading KIT Mutations and Treatment Outcomes in Advanced Gastrointestinal Stromal Tumor

Revealing Transactions: Inspire Investing’s Reduction in Myriad Genetics and Insider Selling

Intriguing Transactions in the World of Biotechnology: Myriad Genetics, Inc. and Inspire Investing LLC July 12, 2023 – In a recent disclosure with the Securities and Exchange Commission (SEC), it has been discovered that Inspire Investing LLC has made significant changes to its investment portfolio. The well-known investment firm drastically…

Continue Reading Revealing Transactions: Inspire Investing’s Reduction in Myriad Genetics and Insider Selling

Genomenon Acquires Boston Genetics for Rapid Human Genome Curation

Mike Klein, CEO of the genomic health company Genomenon, told GEN Edge that the company’s tracking system identifies about 15,000 newly published, peer-reviewed research articles per week with genomics data—or roughly 750,000 per year! But Klein said that one of the things that researchers, whether in industry or academia, have…

Continue Reading Genomenon Acquires Boston Genetics for Rapid Human Genome Curation

Increasing Applications of Transcriptome Sequencing in Life Science for Capturing Polyadenylated RNA

DUBLIN, July 10, 2023 /PRNewswire/ — The “RNA Analysis Market Size, Share & Trends Analysis Report By Product (Kits & Reagents, Services, Instruments), By Technology (qPCR, Microarray, Sequencing), By Application, By End-use And Segment Forecasts, 2023-2030” report has been added to ResearchAndMarkets.com’s offering. Research_and_Markets_Logo The global RNA analysis market size is…

Continue Reading Increasing Applications of Transcriptome Sequencing in Life Science for Capturing Polyadenylated RNA

TScan teams with Tempus to develop companion diagnostic for cancer cell therapy

TScan Therapeutics has partnered with Tempus to develop a companion diagnostic to inform treatment of patients in a clinical trial of its oncology cell therapies. Massachusetts-based TScan is developing T-cell receptor (TCR)-engineered T-cell therapies (TCR-T), for which the biotech firm profiles the tumors of patients and engineers their own T…

Continue Reading TScan teams with Tempus to develop companion diagnostic for cancer cell therapy

Allspring Global Investments Holdings LLC Drastically Increases Ownership in Myriad Genetics, Inc. as Company Makes Strides in Genetic Testing and Precision Medicine

In a surprising turn of events, Allspring Global Investments Holdings LLC has drastically increased its ownership in Myriad Genetics, Inc. (NASDAQ:MYGN) by an astonishing 627.3% during the first quarter of this year. This revelation comes from the company’s recent 13F filing with the Securities and Exchange Commission, which disclosed that…

Continue Reading Allspring Global Investments Holdings LLC Drastically Increases Ownership in Myriad Genetics, Inc. as Company Makes Strides in Genetic Testing and Precision Medicine

Ronald Blue Trust Inc. Purchases 2,350 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Ronald Blue Trust Inc. grew its position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 26.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,378 shares of the company’s stock after acquiring an…

Continue Reading Ronald Blue Trust Inc. Purchases 2,350 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Foundation Medicine Releases New Data at ASCO on Use of HRD Algorithm in Early Breast and Ovarian Cancer, Enhancing Evidence Build

At ASCO 2023, Foundation Medicine presented two new analyses supporting the use of their innovative Homologous recombination deficiency signature (HRDsig) for detecting genomic scars from patient tissue samples analyzed using FoundationOneCDx or FoundationOne, expanding upon clinical evidence published over the past year. These findings, the researchers say, support HRDsig as…

Continue Reading Foundation Medicine Releases New Data at ASCO on Use of HRD Algorithm in Early Breast and Ovarian Cancer, Enhancing Evidence Build

Sequential and directional insulation by conserved CTCF sites underlies the Hox timer in stembryos

Timecourse of Hox gene activation in stembryos In gastrulating mouse embryos, Wnt signaling contributes to the formation of the primitive streak from epiblast cells. Likewise, in stembryos cultured as described in ref. 34, a pulse of the Wnt agonist Chiron 48 h after aggregation of mES cells, that is, between 48 h…

Continue Reading Sequential and directional insulation by conserved CTCF sites underlies the Hox timer in stembryos

Global Minimally Invasive Biopsy Techniques Market

New York, June 15, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Minimally Invasive Biopsy Techniques Market Assessment, By Product Offered, By Technique, By Circulating Biomarker, By Application, By End-user, By Region, Opportunities and Forecast, 2016-2030F” – www.reportlinker.com/p06468091/?utm_source=GNW Global Minimally Invasive Biopsy Techniques Market size was…

Continue Reading Global Minimally Invasive Biopsy Techniques Market

Bioinformatics Scientist – Predicine, Inc

Predicine is a global molecular insights company committed to advancing precision medicine in oncology and infectious disease diagnostics. Predicine is developing proprietary technologies for cell-free DNA and cell-free RNA liquid biopsy to enable minimally invasive molecular diagnoses for early cancer detection, treatment selection, therapy response, minimal residual disease monitoring, and…

Continue Reading Bioinformatics Scientist – Predicine, Inc

Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics

NEW YORK – Roche subsidiary Foundation Medicine and German pharmaceutical company Merck KGaA announced on Monday that they have entered a strategic collaboration to develop companion diagnostics for the US market.  The companies will develop the FoundationOne CDx and FoundationOne Liquid CDx tests as companion diagnostics for selected marketed and…

Continue Reading Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics

Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research

SAN DIEGO and SAN JOSE, Calif. , June 2, 2023 /PRNewswire/ — Invivoscribe and Complete Genomics announced today that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics’ NGS platforms. The territory is worldwide, and the field is oncology and cancer research. Under the terms…

Continue Reading Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research

Liquid Biopsy Holds Promise in Prostate Cancer Diagnosis

Given the shortcomings of conventional biopsy, liquid biopsy offers a different strategy as a cutting-edge diagnostic tool.1 By examining the circulating blood components, it is possible to assess the limiting factors more accurately for better treatment choices—clonal variations and heterogeneity. Additionally, liquid biopsy provides a more accurate representation of the…

Continue Reading Liquid Biopsy Holds Promise in Prostate Cancer Diagnosis

Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting

New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance PALO ALTO, Calif., May 31, 2023–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data…

Continue Reading Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting

Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan APAC – English USA – English

SAN DIEGO, May 26, 2023 /PRNewswire/ — Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan’s Ministry of Health, Labor and Welfare (MHLW) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be…

Continue Reading Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan APAC – English USA – English

Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan, Business News

SAN DIEGO, May 26, 2023 /PRNewswire/ — Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan’s Ministry of Health, Labor and Welfare (MHLW) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may…

Continue Reading Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan, Business News

An integrated tumor, immune and microbiome atlas of colon cancer

Samples used in this observational cohort study (tumor tissue and matched healthy colon tissue, AC-ICAM cohort) are from patients with colon cancer diagnosed at Leiden University Medical Center, the Netherlands, from 2001 to 2015 that did not object for future use of human tissues for scientific research and that were…

Continue Reading An integrated tumor, immune and microbiome atlas of colon cancer

Bioinformatics Analyst Job Opening in Hayward, CA at Predicine, Inc

Predicine is a global molecular insights company committed to advancing precision medicine in oncology and infectious disease diagnostics. Predicine is developing proprietary technologies for cell-free DNA and cell-free RNA liquid biopsy to enable minimally invasive molecular diagnoses for early cancer detection, treatment selection, therapy response, minimal residual disease monitoring, and…

Continue Reading Bioinformatics Analyst Job Opening in Hayward, CA at Predicine, Inc

Senior / Staff Software Engineer, Production Bioinformatics Job Opening in Hayward, CA at Predicine, Inc

Predicine is a global molecular insights company committed to advancing precision medicine in oncology and infectious disease diagnostics. Predicine is developing proprietary technologies for cell-free DNA and cell-free RNA liquid biopsy to enable minimally invasive molecular diagnoses for early cancer detection, treatment selection, therapy response, minimal residual disease monitoring, and…

Continue Reading Senior / Staff Software Engineer, Production Bioinformatics Job Opening in Hayward, CA at Predicine, Inc

Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Test

69 11.05.2023 – 16:59 Invivoscribe, Inc. San Diego (ots/PRNewswire) SAN DIEGO, May 11, 2023 /PRNewswire/– “We are pleased to announce today that the LeukoStrat® CDx flt3 -Invivoscribe’s mutation test has been approved by BSI (Netherlands) and EMA as a Class C CDx test that meets the stringent new IVDR requirements…

Continue Reading Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Test

Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay

SAN DIEGO, May 11, 2023 /PRNewswire/ — “Today we are pleased to announce that Invivoscribe’s LeukoStrat® CDx FLT3 Mutation Assay has been approved by BSI (Netherlands) and the EMA as a Class C CDx assay, meeting the stringent new IVDR (Regulation (EU) 2017/746) requirements. Invivoscribe is one of the first companies…

Continue Reading Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay

VCU technology could upend DNA sequencing for diagnosing certain DNA mutations

Doctors are increasingly using genetic signatures to diagnose diseases and determine the best course of care, but using DNA sequencing and other techniques to detect genomic rearrangements remains costly or limited in capabilities. However, an innovative breakthrough developed by researchers at Virginia Commonwealth University Massey Cancer Center and the VCU…

Continue Reading VCU technology could upend DNA sequencing for diagnosing certain DNA mutations

Codexis Reports First Quarter 2023 Financial Results

Codexis, Inc. CDX-7108 Clinical Development Program Remains on Track       Estimated Cash Runway Through End of 2024 Funds Important Upcoming Milestones Company Reiterates 2023 Total Revenue Guidance with Adjustments to Product vs. R&D Revenue Mix and Range on Gross Margin REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) —…

Continue Reading Codexis Reports First Quarter 2023 Financial Results

Tempus granted FDA premarket approval for colorectal cancer CDx

Tempus on Monday announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) for its xT CDx sequencing test as a companion diagnostic. xT CDx is a 648-gene next-generation sequencing test (NGS) for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for…

Continue Reading Tempus granted FDA premarket approval for colorectal cancer CDx

Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device

xT CDx is the company’s first Premarket Approval from the FDA CHICAGO, May 01, 2023–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its companion diagnostic test, xT CDx….

Continue Reading Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device

Tempus Gains FDA Premarket Approval for NGS Solid Tumor Profiling Test

NEW YORK – Tempus said Monday that the US Food and Drug Administration has given premarket approval for the firm’s companion diagnostic test for colorectal cancer treatment. Chicago-based Tempus’ xT CDx is a 648-gene next-generation sequencing test that can be used to provide solid tumor profiling in cancer patients with…

Continue Reading Tempus Gains FDA Premarket Approval for NGS Solid Tumor Profiling Test

FDA Approves xT CDx, a NGS-Based in Vitro Diagnostic Device

The FDA has approved xT CDx, a 648-gene next-generation sequencing (NGS) assay for solid tumor profiling, and companion diagnostic for patients with colorectal cancer.1 The qualitative NGS-based in vitro diagnostic device is intended to be leveraged to identify substitutions like single nucleotide variants and multinucleotide variants and insertion and deletion…

Continue Reading FDA Approves xT CDx, a NGS-Based in Vitro Diagnostic Device

DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023

DiaCarta, Ltd. Abstracts demonstrating XNA technology’s improvements to assay sensitivity across different technology platforms and support for use in companion diagnostics (CDx) assay development Additional abstracts to further support XNA technology’s potential for use in minimal residual disease (MRD) monitoring of residual cancer cells PLEASANTON, Calif., April 16, 2023 (GLOBE…

Continue Reading DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023

Moderna’s (MRNA) mRNA-4157 in combo with Merck’s (MRK) KEYTRUDA reduced the risk of recurrence or death by 44% in melanoma patients

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Moderna, Inc. (Nasdaq: MRNA) and Merck (NYSE: MRK) announced the first presentation of detailed results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination…

Continue Reading Moderna’s (MRNA) mRNA-4157 in combo with Merck’s (MRK) KEYTRUDA reduced the risk of recurrence or death by 44% in melanoma patients

ctDNA Genomic Profiling Can Guide Targeted Therapy in Advanced Cancer

Genomic profiling of circulating tumor DNA (ctDNA) with a large panel appeared feasible in a routine setting and helped to obtain relevant molecular information that could inform strategies with targeted therapies for patients with metastatic solid tumors, according to findings from the prospective PRISM study published in Annals of Oncology….

Continue Reading ctDNA Genomic Profiling Can Guide Targeted Therapy in Advanced Cancer

Carrier Screening Market is projected to exhibit a CAGR of 12.4% from 2023 to 2033 | Exclusive Report by FMI

The global carrier screening market is expected to record a CAGR of 12.4% between 2023 and 2033, with a size estimated in 2023 at US$ 1,343.40 million. The market’s value is expected to rise to US$ 4,323.84 million by 2033. As a result of increased funding from the public and commercial sectors…

Continue Reading Carrier Screening Market is projected to exhibit a CAGR of 12.4% from 2023 to 2033 | Exclusive Report by FMI

Foundation Medicine to collaborate with Bristol Myers Squibb on companion diagnostic for solid tumors

Molecular profiling company Foundation Medicine on Tuesday announced a collaboration with Bristol Myers Squibbto develop the FoundationOne CDx test as a companion diagnostic to repotrectinib, Bristol Myers Squibb’s investigational tyrosine kinase inhibitor (TKI). Repotrectinib is currently being evaluated in a phases I and II study, TRIDENT-1, for patients with TKI-naïve…

Continue Reading Foundation Medicine to collaborate with Bristol Myers Squibb on companion diagnostic for solid tumors

Foundation Medicine, Bristol Myers Squibb Expand CDx Partnership to Investigational Cancer Drug

NEW YORK – Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to include companion diagnostic development for the pharma firm’s investigational tyrosine kinase inhibitor repotrectinib. Repotrectinib is an orally administered tyrosine kinase inhibitor that is being evaluated in an ongoing registrational Phase I/II…

Continue Reading Foundation Medicine, Bristol Myers Squibb Expand CDx Partnership to Investigational Cancer Drug

Bioinformatics Market Size to Grow USD 24,731.61 Million by 2027 at a CAGR of 13.4%

BANGALORE, India, March 28, 2023 /PRNewswire/ — The Global Bioinformatics Market is Segmented by Technology & Services (Knowledge Management Tools, Bioinformatics Platforms, and Bioinformatics Services), Application (Metabolomics, Molecular Phylogenetics, Transcriptomics, Proteomics, Chemoinformatics, Genomics, and Others), and Sector (Medical Bioinformatics, Animal Bioinformatics, Agriculture Bioinformatics, Academics, and Others). The global bioinformatics market size…

Continue Reading Bioinformatics Market Size to Grow USD 24,731.61 Million by 2027 at a CAGR of 13.4%

Incyte’s Pemazyre Approved in Japan for FGFR1-Positive Rare Blood Cancers

NEW YORK – Incyte said on Monday that that the Japanese Ministry of Health, Labor, and Welfare approved Pemazyre (pemigatinib) for treatment of patients with myeloid or lymphoid neoplasms (MLNs) bearing FGFR1 fusions. The agency’s decision was based on the Phase II FIGHT-203 trial, in which Wilmington, Delaware-based Incyte established…

Continue Reading Incyte’s Pemazyre Approved in Japan for FGFR1-Positive Rare Blood Cancers

Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms

Knockdown of LFPRLR reduces splenic B-cell subsets in SLE-prone mice To investigate whether the PRL-LFPRLR axis raises the risk of initiation of B-cell malignancies, we compared SLE-prone MRL-lpr mice treated with either control SMO or LFPRLR SMO. Among SLE-prone models, we chose MRL-lpr mice because they accumulate genetic lesions indicative…

Continue Reading Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms

Phase 3 Trial of Fablyn Plus Verzinio for Metastatic Breast Cancer Initiates Registration

An upcoming phase 3 clinical trial will compare the safety and efficacy of Fablyn (lasofoxifene) plus Verzinio (abemaciclib) to the standard treatment of Faslodex (fulvestrant) plus Verzinio in pre- and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation. The randomized multicenter study will enroll…

Continue Reading Phase 3 Trial of Fablyn Plus Verzinio for Metastatic Breast Cancer Initiates Registration

Advanced Cancer Outcomes Predicted Using Model Based on Circulating Tumor DNA Metrics

NEW YORK – A team from Genentech, Foundation Medicine, and elsewhere has come up with a machine learning model for bringing together a range of circulating tumor DNA (ctDNA) metrics to predict treatment response and related survival patterns in advanced lung cancer patients — an approach that is expected to…

Continue Reading Advanced Cancer Outcomes Predicted Using Model Based on Circulating Tumor DNA Metrics

FDA Expands Indication for Illuccix for PSMA Radioligand Selection in Prostate Cancer

The FDA has approved an expanded indication for Illuccix (TLX591-CDx), a kit that prepares for Ga-68 PSMA-11 PET injection, to allow for the selection of patients with metastatic prostate cancer who may benefit from prostate-specific membrane antigen (PSMA)–directed radioligand 177Lu-PSMA-617 (Pluvicto), according to a press release from Telix Pharmaceuticals.1 “[Illuccix]…

Continue Reading FDA Expands Indication for Illuccix for PSMA Radioligand Selection in Prostate Cancer

ELAINE-3 Study of Lasofoxifene Initiates for ESR1-Mutated ER+/HER2- Breast Cancer

A phase 3 study has commenced which will compare targeted lasofoxifene in combination with the CDK 4/6 inhibitor abemaciclib vs fulvestrant (Faslodex) plus abemaciclib (Verzenio) in pre- and post-menopausal patients with locally advanced or metastatic estrogen receptor (ER)-positive/HER2-negative breast cancer with an ESR1 mutation, according to Sermonix Pharmaceuticals Inc. “The…

Continue Reading ELAINE-3 Study of Lasofoxifene Initiates for ESR1-Mutated ER+/HER2- Breast Cancer

Urothelial Carcinoma Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

PRESS RELEASE Published March 13, 2023 DelveInsight’s, “Urothelial Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including Urothelial Carcinoma clinical trials and nonclinical stage products. It also covers the…

Continue Reading Urothelial Carcinoma Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

Advances in the detection, characterization, and monitoring of cancer in pets

Content sponsored by Blue Buffalo. Historically, physicians have identified cancer in humans and animals through the appearance of an obvious mass/lump or the development of clinical signs that typically occur when a tumor is advanced (weight loss, vomiting, coughing, etc). Over the past few decades, technologies have improved substantially to…

Continue Reading Advances in the detection, characterization, and monitoring of cancer in pets

QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact

QIAGEN N.V.QGEN recently announced that it has entered into a strategic partnership with Servier. The agreement is intended to develop a companion diagnostic test for TIBSOVO — an isocitrate dehydrogenase-1 or IDH1 inhibitor indicated for treating the blood cancer acute myeloid leukemia or AML. For investors’ note, QIAGEN has master…

Continue Reading QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact

Sermonix Pharma Using Guardant Health CDx to Screen Breast Cancer Patients for Lasofoxifene Trial

NEW YORK – Sermonix Pharmaceuticals is starting a Phase III trial of endocrine therapy lasofoxifene for patients with locally advanced or metastatic ER+/HER2-breast cancer with an estrogen receptor 1 (ESR1) mutation, the company said on Thursday. Sermonix has partnered with Guardant Health for the trial and will use the Guardant360…

Continue Reading Sermonix Pharma Using Guardant Health CDx to Screen Breast Cancer Patients for Lasofoxifene Trial

Sermonix Pharmaceuticals Announces Initiation of Phase 3

Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic development Phase 3 study is supported by previously presented ELAINE-1 and ELAINE-2 Phase 2 study results Sermonix anticipates dosing the first patient in first half of 2023 COLUMBUS, Ohio and PALO ALTO, Calif.,…

Continue Reading Sermonix Pharmaceuticals Announces Initiation of Phase 3

Carrier Screening Market to Reach USD 4,323.84 Million, by

NEWARK, Del, March 08, 2023 (GLOBE NEWSWIRE) — The global carrier screening market is expected to record a CAGR of 12.4% between 2023 and 2033, with a size estimated in 2023 at US$ 1,343.40 million. The market’s value is expected to rise to US$ 4,323.84 million by 2033. As a…

Continue Reading Carrier Screening Market to Reach USD 4,323.84 Million, by

Illumina, Myriad Genetics Expand Partnership to Bring TSO 500 HRD Assay to US

NEW YORK – Illumina and Myriad Genetics said on Thursday that they have expanded their strategic partnership on homologous recombination deficiency (HRD) testing. Under the terms of the agreement, Illumina’s TruSight Oncology 500 HRD research-use-only assay will now be available in the US. Illumina will offer distributable kits while Myriad will…

Continue Reading Illumina, Myriad Genetics Expand Partnership to Bring TSO 500 HRD Assay to US

Point32Health Expands Coverage of Foundation Medicine CDx Tests for Patients With Advanced Cancer

NEW YORK – Foundation Medicine said on Thursday that its companion diagnostic comprehensive genomic profiling tests will be made available to certain cancer patients under Point32Health’s health plans through an expansion of coverage criteria. Under the value-based agreement, the FoundationOne CDx and FoundationOne Liquid CDx assays will be available to…

Continue Reading Point32Health Expands Coverage of Foundation Medicine CDx Tests for Patients With Advanced Cancer

Results from Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma

(UroToday.com) The 2023 GU ASCO annual meeting included an oral abstract session on renal cell carcinoma (RCC), featuring a presentation by Dr. Brian Shuch discussing results from ZIRCON, a phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of clear cell RCC. The increasing detection of renal masses presents a significant patient…

Continue Reading Results from Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma

Roche, Janssen expand collaboration to develop CDx tests for targeted therapies

Roche announced Thursday that it has expanded its collaboration with Janssen Biotech to develop companion diagnostics for targeted therapies. Roche said that the expanded agreement broadens opportunities for Roche and Janssen to collaborate in the precision medicine field with multiple companion diagnostics technologies, including immunohistochemistry (IHC), digital pathology, next generation…

Continue Reading Roche, Janssen expand collaboration to develop CDx tests for targeted therapies

The chances of Phase 3 success, and the ASX health stocks that are close a home run

What is the probability of having Phase 3 success, and is Phase 4 required? Stockhead reached out to Cynata’s CMO, Dr Jolanta Airey We look at ASX stocks with ongoing Phase 3 trials   In order to progress to the Phase 3 clinical trials, a drug must have demonstrated promising…

Continue Reading The chances of Phase 3 success, and the ASX health stocks that are close a home run

Investment in Advanced Technology by Leading Firms to Pump Up Future Market Expansion; Carrier Screening Market to Grow at a CAGR of 12.4% through 2033.

The global carrier screening market is expected to record a CAGR of 12.4% between 2023 and 2033, with a size estimated in 2023 at US$ 1,343.40 million. The market’s value is expected to rise to US$ 4,323.84 million by 2033. As a result of increased funding from the public and…

Continue Reading Investment in Advanced Technology by Leading Firms to Pump Up Future Market Expansion; Carrier Screening Market to Grow at a CAGR of 12.4% through 2033.

Next Generation Sequencing at the Forefront of Precision Medicine

World Cancer Day offers a platform to raise the awareness of the latest advancements in oncology that are changing both the treatment of patients and the practice of clinicians around the world. In this regard, Next Generation Sequencing (NGS) continues to be at the forefront of precision medicine in oncology….

Continue Reading Next Generation Sequencing at the Forefront of Precision Medicine

Hemato Oncology Testing Market to Witness Massive Growth by Abbott Laboratories, Thermo Fisher Scientific, QIAGEN N.V.

The Global Hemato Oncology Testing Market 2032 Industry Report is a professional and in-depth study on the current state of the Hemato Oncology Testing Market by QMI. The Hemato Oncology Testing Market is supposed to demonstrate a considerable growth during the forecast period of 2023-2032. The company profiles of all…

Continue Reading Hemato Oncology Testing Market to Witness Massive Growth by Abbott Laboratories, Thermo Fisher Scientific, QIAGEN N.V.

SG Americas Securities LLC sells Myriad Genetics, Inc. (NASDAQ:MYGN) stock.

During the third quarter, SG Americas Securities LLC sold off 43.4% of its holdings in Myriad Genetics, Inc. (NASDAQ: MYGN) shares, as stated in the most recent SEC filing that the company submitted. The company now owns a total of 29,966 of the company’s shares of the stock following the…

Continue Reading SG Americas Securities LLC sells Myriad Genetics, Inc. (NASDAQ:MYGN) stock.

Week in Review: Abbott sees headwinds easing; Qiagen 25-minute whole genome analysis; liquid biopsy market growth; more

Dear LabPulse.com reader, Abbott Chairman and CEO Robert Ford on Wednesday said he sees an easing of challenges affecting the company’s businesses at the start of 2023 and anticipates organic sales growth this year in the high single digits, excluding COVID-19 testing sales. The firm booked diagnostics segment revenues of…

Continue Reading Week in Review: Abbott sees headwinds easing; Qiagen 25-minute whole genome analysis; liquid biopsy market growth; more

Thermo Fisher Scientific, AstraZeneca to develop solid tissue and blood-based CDx for NSCLC

Thermo Fisher Scientific announced on January 24 that it is working with AstraZeneca as part of a global, multiyear agreement to develop a solid tissue and blood-based companion diagnostic (CDx) test for the biopharma firm’s Tagrisso (osimertinib) non-small cell lung cancer (NSCLC) treatment. The test would identify patients with NSCLC…

Continue Reading Thermo Fisher Scientific, AstraZeneca to develop solid tissue and blood-based CDx for NSCLC

Foundation Medicine, Karyopharm Therapeutics Partnering on Endometrial Cancer CDx

NEW YORK – Foundation Medicine and Karyopharm Therapeutics said Tuesday they are collaborating on a companion diagnostic for Karyopharm’s experimental drug Xpovio (selinexor), which is in development as a maintenance therapy for patients with advanced or recurrent TP53 wild-type endometrial cancer. The partnership between the two Massachusetts-based firms will use…

Continue Reading Foundation Medicine, Karyopharm Therapeutics Partnering on Endometrial Cancer CDx

Qiagen, Helix Partner for Hereditary Disease CDx Development

NEW YORK – Helix and Qiagen have formed an exclusive global partnership to develop and commercialize companion diagnostics for hereditary diseases, the firms announced on Thursday. Financial terms of the partnership were not disclosed. The collaboration will address the health burden of hereditary neurodegenerative, cardiovascular, autoimmune, and inflammatory diseases, the…

Continue Reading Qiagen, Helix Partner for Hereditary Disease CDx Development

Global KRAS Inhibitors Market & Clinical Trials Forecast Report to 2028 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global KRAS Inhibitors Market & Clinical Trials Forecast 2028” report has been added to ResearchAndMarkets.com‘s offering. The advancement in clinical research has led to the identification of several oncogenes that are generally mutated in cancers. Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most frequently mutated…

Continue Reading Global KRAS Inhibitors Market & Clinical Trials Forecast Report to 2028 – ResearchAndMarkets.com

Your Source Of Daily World News Crypto Business Technology & Sports News

Cholangiocarcinoma, or bile duct most cancers, is lethal even when caught early. The 5-year survival rate amongst these identified early is 17% to 25%; for many sufferers, the speed is under 10%. Experts say the important thing to bettering these dismal statistics is to give attention to the various genetic…

Continue Reading Your Source Of Daily World News Crypto Business Technology & Sports News

New Products Posted to GenomeWeb: Myriad Genetics, Invitae, Seqster, More

Myriad Genetics Precise Oncology Solutions  Myriad Genetics announced the launch of Precise Oncology Solutions, a new service through which oncologists can order its BRACAnalysis CDx and MyChoice CDx; its MyRisk Hereditary Cancer Test; and the Precise Tumor Molecular Profile Test, which is performed at a CLIA-certified lab operated by Intermountain…

Continue Reading New Products Posted to GenomeWeb: Myriad Genetics, Invitae, Seqster, More

Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare … | News

– Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) – – New patent granted for PRA023 companion diagnostic (CDx) reinforces Prometheus’ precision approach and extends CDx patent coverage into 2040 – – Company to present today…

Continue Reading Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare … | News

Very important pharmacogene variants in the Blang population

Introduction The use of drugs should be different among diverse ethnic groups because of differences in ethnicity, age, sex, environmental factors and genetic factors. If these differences are ignored, then drug sensitivity, metabolic rate, and adverse reactions are affected, which influences the curative effect of drugs and aggravates the illness…

Continue Reading Very important pharmacogene variants in the Blang population

Establishment of sunitinib-resistant CDX model of ccRCC

Introduction Renal cell carcinoma (RCC) accounts for approximately 2–3% of all malignant tumors, and its prevalence is rising. Metastatic RCC accounts for 25–30% of all RCC cases, and has an exceedingly poor prognosis.1 In 2020, among approximately 430,000 newly discovered cases of RCC, 179,000 died.2 Clear cell renal cell carcinoma…

Continue Reading Establishment of sunitinib-resistant CDX model of ccRCC

Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test for Investigational Lymphoma Treatment

NEW YORK – Qiagen and Denovo Biopharma said on Thursday that they are collaborating to develop a blood-based companion diagnostic test to identify patients expressing a genomic biomarker who are likely to respond to Denovo’s investigational DB102 treatment for diffuse large B-cell lymphoma. Under the agreement, Qiagen will develop an…

Continue Reading Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test for Investigational Lymphoma Treatment